Literature DB >> 3738945

The beneficial effect of intracarotid urokinase on acute stroke in a baboon model.

G J Del Zoppo, B R Copeland, T A Waltz, J Zyroff, E F Plow, L A Harker.   

Abstract

The capacity of intracarotid infusion of urokinase to salvage neurologic function in a baboon model of acute thrombotic stroke has been studied. The model consists of reversible eccentric balloon compression (3 hours) of the right middle cerebral artery (MCA) proximal to the take-off of the lenticulostriate arteries (LSA), resulting in in situ thrombosis of perforating branches supplying the right corpus striatum. Neurologic endpoints included quantitative assessment of neurologic function (NE), estimation of cerebral infarction volume by computerized tomographic (CT) scan, and carotid angiography. In untreated acute stroke control animals (n = 6), a persistent decrease in functional score (from 100 to 36 +/- 11) at 14 days and a defined region of cerebral infarction (volume = 3.2 +/- 1.5) were detected at 10 days. Intracarotid urokinase administered to five animals (1.2 X 10(6) IU over 60 min) following the 3 hour period of MCA occlusion improved neurologic function (NE = 50, 55, 85, 100, 100) and reduced infarction size (0.3, 0.5, 0.8, 0.7, 1.1 cm3, respectively) without evidence of intracranial hemorrhage. Systemic fibrinogenolysis was produced in all five treated animals. We conclude that thrombolytic therapy given within 3 hours of experimental thrombotic occlusion may salvage neurologic function and reduce cerebral infarction volume without CT scan detectable intracranial bleeding.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3738945     DOI: 10.1161/01.str.17.4.638

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  15 in total

Review 1.  Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke.

Authors:  Rais Reskiawan A Kadir; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2019-09-24       Impact factor: 5.046

2.  Thrombolytic therapy for acute stroke.

Authors:  P D Lyden
Journal:  West J Med       Date:  1989-05

Review 3.  Thrombolytic therapy for stroke: a review with particular reference to elderly patients.

Authors:  K W Muir; M Roberts
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 4.  Experimental intracerebral hemorrhage: avoiding pitfalls in translational research.

Authors:  Matthew A Kirkman; Stuart M Allan; Adrian R Parry-Jones
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-24       Impact factor: 6.200

Review 5.  Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.

Authors:  L Candelise; C Roncaglioni; E Aritzu; A Ciccone; A P Maggioni
Journal:  Ital J Neurol Sci       Date:  1996-02

Review 6.  Experimental animal models and inflammatory cellular changes in cerebral ischemic and hemorrhagic stroke.

Authors:  Tao Yan; Michael Chopp; Jieli Chen
Journal:  Neurosci Bull       Date:  2015-12-02       Impact factor: 5.203

Review 7.  Thrombolysis in acute ischaemic stroke.

Authors:  A C Pereira; P J Martin; E A Warburton
Journal:  Postgrad Med J       Date:  2001-03       Impact factor: 2.401

8.  Thrombolytic Therapy for Acute Ischemic Stroke.

Authors:  Patrick D Lyden
Journal:  Stroke       Date:  2019-07-22       Impact factor: 7.914

Review 9.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 10.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.